Tuberculosis
Recent clinical, regulatory, research and industry developments relating to this disease.
Gender and sex differences in occupation-specific infectious diseases: a systematic review.
Tuberculosis and diabetes mellitus: The complexity of the comorbid interactions.
Immune mechanisms of granuloma formation in sarcoidosis and tuberculosis.
Tuberculosis and COVID-19 in the elderly: factors driving a higher burden of disease.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 4 clinical trials expected to report results, the earliest in Q1 2029.
- Active recent publication activity.
- 1 industry development reported.
- Q1 2029A Pan-Ultrashort Regimen for Drug-susceptible and Drug-resistant Pulmonary Tuberculosis: A Multi-Center Randomized Controlled Trial
- Q4 2029Six Weeks of Daily Rifapentine vs. a Comparator Arm of 12-16 Week Rifamycin-based Treatment of Latent M. Tuberculosis Infection: Assessment of Safety, Tolerability and Effectiveness
- Q1 2030Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis: A Phase III Randomized Control Trial (Doxy-TB)
- Q3 2031Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis (PRISM-TB)
Research HighlightsViewHide
- 2025-09-30Genetic Susceptibility to Tuberculosis and the Utility of Polygenic Scores in Population Stratification.Dashian MA · 2025
Clinical MilestonesViewHide
- 2026-06-09Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis: A Phase III Randomized Control Trial (Doxy-TB)Results expected Q1 2030
- 2026-05-06Six Weeks of Daily Rifapentine vs. a Comparator Arm of 12-16 Week Rifamycin-based Treatment of Latent M. Tuberculosis Infection: Assessment of Safety, Tolerability and EffectivenessResults expected Q4 2029
- 2026-01-20Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis (PRISM-TB)Results expected Q3 2031
- 2025-12-01A Pan-Ultrashort Regimen for Drug-susceptible and Drug-resistant Pulmonary Tuberculosis: A Multi-Center Randomized Controlled TrialResults expected Q1 2029
- 2026-01-16One-month Latent Tuberculosis Treatment for Renal Transplant CandidatesPrimary completion
- 2025-11-12ANRS 12424: Determination of Adequate Tuberculosis Regimen in Adults and Adolescents Hospitalized With HIV-associated Severe Immune Suppression (CD4 ≤ 100 Cells/µL): the DATURA Trial.Completed
- 2025-09-22A Multicenter, Randomized, Double-blind, Controlled Phase Ⅲ Trial of Recombinant Mycobacterium Tuberculosis Fusion Protein (EC) for the Diagnosis of Mycobacterium Tuberculosis Infection in 65-year-olds and AboveCompleted
Industry & MarketViewHide
- 2026-08-03Spatial-temporal analysis and influencing factors of pulmonary tuberculosis in Fuzhou, China from 2014 to 2022Industry · Nature — Environmental Sciences
- 2026-08-03IndustrySpatial-temporal analysis and influencing factors of pulmonary tuberculosis in Fuzhou, China from 2014 to 2022Industry · Nature — Environmental Sciences
- 2026-06-09ClinicalDoxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis: A Phase III Randomized Control Trial (Doxy-TB)Results expected Q1 2030
- 2026-05-06ClinicalSix Weeks of Daily Rifapentine vs. a Comparator Arm of 12-16 Week Rifamycin-based Treatment of Latent M. Tuberculosis Infection: Assessment of Safety, Tolerability and EffectivenessResults expected Q4 2029
- 2026-01-20ClinicalProgram for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis (PRISM-TB)Results expected Q3 2031
- 2026-01-16ClinicalA Proof-of Concept, Randomized, Controlled Study of Tuberculosis Immunization With BCG to Prevent Infection in Healthy Adults (TIPI Trial)Terminated
- 2026-01-16ClinicalOne-month Latent Tuberculosis Treatment for Renal Transplant CandidatesPrimary completion
- 2025-12-01ClinicalA Pan-Ultrashort Regimen for Drug-susceptible and Drug-resistant Pulmonary Tuberculosis: A Multi-Center Randomized Controlled TrialResults expected Q1 2029
- 2025-11-12ClinicalANRS 12424: Determination of Adequate Tuberculosis Regimen in Adults and Adolescents Hospitalized With HIV-associated Severe Immune Suppression (CD4 ≤ 100 Cells/µL): the DATURA Trial.Completed
- 2025-09-30ResearchGenetic Susceptibility to Tuberculosis and the Utility of Polygenic Scores in Population Stratification.Dashian MA · 2025
- 2025-09-22ClinicalA Multicenter, Randomized, Double-blind, Controlled Phase Ⅲ Trial of Recombinant Mycobacterium Tuberculosis Fusion Protein (EC) for the Diagnosis of Mycobacterium Tuberculosis Infection in 65-year-olds and AboveCompleted
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approval — Dovprela is indicated in combination with bedaquiline and linezolid, in adults, for the t… (2020)
Approval — Sirturo is indicated for use as part of an appropriate combination regimen in adult… (2014)
Approval — Deltyba is indicated for use as part of an appropriate combination regimen for pulmonary… (2014)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Tuberculosis15
- Mycobacterium tuberculosis9
- Communicable Diseases2
- COVID-192
- Latent Tuberculosis2
- Acquired Immunodeficiency Syndrome1
- Adaptive Immunity1
- B-Lymphocytes1
Leading journals6
- Frontiers in immunology3
- International journal of molecular sciences2
- The European respiratory journal2
- Annals of clinical microbiology and antimicrobials1
- Cell reports1
- Cellular & molecular immunology1
Leading researchers8
- Cirillo DM2
- Goletti D2
- Kampmann B2
- Keane J2
- Migliori GB2
- Zellweger JP2
- Adlhoch C1
- Alffenaar JW1
Affiliations (unnormalised)6
- Yong Loo Lin School of Medicine2
- "L. Spallanzani" National Institute for Infectious Diseases (INMI)1
- Africa Health Research Institute1
- Aga Khan University Hospital1
- Beatrice & Samuel A. Seaver Laboratory1
- Beijing Chest Hospital1
Disease biology
Key proteins & gene products studied in this disease. Number shows shared papers.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Tuberculosis is an infectious disease caused by species of Mycobacterium tuberculosis in humans and other animals. The literature distinguishes active tuberculosis disease from latent tuberculosis infection, in which infected individuals have no clinical evidence of disease.
Tuberculosis is caused by infection with Mycobacterium tuberculosis. The supplied grounding also notes that disease can remain latent after infection, but it does not support additional causal factors beyond the organism itself.
After inhalation, Mycobacterium tuberculosis is phagocytosed by alveolar macrophages in the lungs. The literature emphasizes host-pathogen interactions, innate immunity, cytokine signaling, and other signal transduction processes in the immune response to infection.
The supplied grounding supports exposure to aerosol droplets containing Mycobacterium tuberculosis as the main risk for transmission. It also indicates that tuberculosis control is more difficult where health services are strained and TB is endemic, but it does not provide specific individual risk factors beyond infection exposure.
Standard care in the supplied grounding centers on diagnosis of active tuberculosis disease and latent tuberculosis infection, along with prevention and control measures. Treatment is described at the level of drug therapy and multidrug regimens, and prevention includes BCG vaccination.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.